News
Next Generation Proteogenomics to be Used with PNETS
Sharon Gorski, PhD, Genome Sciences Centre, Canada, has recently been awarded a two-year Neuroendocrine Tumor Research Foundation (NETRF)–American Association for Cancer Research (AACR) grant to use a new method of proteogenomic analysis on pancreatic neuroendocrine tumors (PNETs).
2017 Petersen Investigator Award
Laura Banaszynski, Ph.D., University of Texas Southwestern Medical Center – Laura Banaszynski, PhD, has always been passionate about science. After training as a chemical biologist, her innate curiosity pushed her to explore the mysteries of cells as a basic researcher.
Optimizing your survivorship
The experience of NETs profoundly changes people’s lives. Fatigue, isolation, worry, and bothersome physical side effects can disrupt daily activities. Here are some simple steps to maintain optimal health and balance during and after cancer care.
Recognizing Outstanding Achievement
A NETRF-funded researcher earned the highest honor from the American Society of Clinical Oncology (ASCO) on June 3, 2017 as part of its Annual Meeting in Chicago. Carl June, MD, University of Pennsylvania, received the David A. Karnofsky Memorial Award for outstanding contributions to cancer research, diagnosis, and treatment.
Study shows rising rates of NET incidence, prevalence, and survival
Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.
Accelerating our understanding of neuroendocrine tumors to find better treatments
Growing small intestinal organoids in a petri dish. Sequencing the “runaway” DNA of a pancreatic neuroendocrine tumor from a blood sample. Evaluating whether environmental or infectious agents contribute to the development of NETs. The research programs funded by NETRF this year push the search for the causes of this disease to the horizon of emerging scientific research.
NETRF Makes $4 Million in Grants to Advance Research of a Poorly Understood Cancer
(April 25, 2017, Boston, MA)—The Neuroendocrine Tumor Research Foundation (NETRF) today announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator
NETRF recognized as top-tier charity
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates
Exploring the Use of Immunotherapy in NETs
NETRF is pleased to announce awards for world-class research to explore the potential of immunotherapy in NETs. This rapidly expanding class of therapies has proven
Petersen Investigator: Michael German, MD
Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical